Back to results
US 8,242,144 B2Granted
Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
AssigneeResverlogix Corp.
InventorsNorman C. W. Wong, Joseph E. L. Tucker, Henrik C. Hansen, Fabrizio S. Chiacchia, David McCaffrey
Life of this patent
Estimating the term…
Abstract
The present disclosure provides non-naturally occurring polyphenol compounds that upregulate the expression of Apolipoprotein A-I (ApoA-I). The disclosed compositions and methods can be used for treatment and prevention of cardiovascular disease and related disease states, including cholesterol or lipid related disorders, such as, e.g., atherosclerosis.
Claims7
A compound of Formula I:
- or a pharmaceutically acceptable salt thereof wherein:
- X is selected from CR11 and N;
- Y is selected from CR12 and N;
- R3 and R8 are each hydroxyl;
- R11 and R12 are each independently selected from alkoxy, aryloxy, alkenyl, amino, aryl, arylalkyl, carbamate, carboxy, cyano, cycloalkyl, ester, ether, formyl, haloalkyl, heteroaryl, heterocyclyl, hydroxyl, ketone, phosphate, sulfide, sulfinyl, sulfonyl, sulfonic acid, sulfonamide and thioketone;
- R1, R5, R6, and R10 are each independently selected from alkoxy, aryloxy, alkyl, alkenyl, alkynyl, amide, amino, aryl, arylalkyl, carbamate, cyano, cycloalkyl, ester, ether, formyl, halogen, haloalkyl, heteroaryl, heterocyclyl, hydrogen, hydroxyl, ketone, nitro, phosphate, sulfide, sulfinyl, sulfonyl, sulfonic acid, sulfonamide and thioketone;
- R2, R4, R7, and R9, are each independently selected from aryloxy, alkyl, alkenyl, alkynyl, amide, amino, aryl, arylalkyl, carbamate, carboxy, cyano, cycloalkyl, ester, ether, formyl, halogen, haloalkyl, heteroaryl, heterocyclyl, hydrogen, hydroxyl, ketone, nitro, phosphate, sulfide, sulfinyl, sulfonyl, sulfonic acid, sulfonamide and thioketone, or
- two adjacent substituents selected from R1, R2, R4, R5, R6, R7, R9, R10, R11, and R12 are connected in a 5 or 6-membered ring to form a bicyclic aryl or bicyclic heteroaryl;
- each W is independently selected from C and N;
- and
- Z is a double bond;
- provided that:
- R2 and R4 are not each hydroxyl;
- at least one W is N;
- when W is N, then p is 0;
- and
- when W is C, then p is 1.
14 more elements
A compound selected from:
- 5-[(E)-2-(4-Hydroxy-phenyl)-vinyl]-pyrazin-2-ol;
- 5-{[1-(4-Hydroxy-phenyl)-meth-(E)-ylidene]-amino}-pyridin-2-ol;
- 5-(4-Hydroxy-phenylazo)-pyridin-2-ol;
- 3-Hydroxymethyl-4-[(E)-2-(4-hydroxy-phenyl)-vinyl]-phenol;
- 2-Hydroxy-5-[(E)-2-(4-hydroxy-phenyl)-vinyl]benzoic acid;
- 3-Nitro-4-[(E)-2-(4-hydroxyphenyl)-vinyl]phenol;
- (E)-Ethyl 2-hydroxy-5-(4-hydroxystyryl)benzoate;
- 4-[(E)-2-(4-Hydroxyphenyl)vinyl]-3-methanesulfonylphenol;
- 3-Amino-4-[(E)-2-(4-hydroxy-phenyl)vinyl]phenol;
- N-{5-Hydroxy-2-[(E)-2-(4-hydroxyphenyl)vinyl]phenyl}-acetamide;
- 5-Hydroxy-2-[2-(4-hydroxyphenyl)vinyl]-N,N-dimethylbenzamide;
- 4-Hydroxy-thiobenzoic acid S-(4-hydroxy-phenyl) ester;
- 4-Hydroxy-benzoic acid pyridin-2-yl ester;
- and pharmaceutically acceptable salts thereof.
11 more elements
Dependencies are inferred from the claim text.